An Insight into the Pathogenesis of Diabetic Cardiomyopathy Along with the Novel Potential Therapeutic Approaches
- 1 January 2024
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 20 (1) , 1
Abstract
Background: The existence of aberrant myocardial activity and function in the exclusion of those other cardiovascular events, such as atherosclerosis, hypertension, and severe valve disease, is known as diabetic cardiomyopathy. Diabetes patients are much more prone to death from cardiovascular illnesses than from any other cause, and they also have a 2–5 fold higher likelihood of acquiring cardiac failure and other complications. Objective: In this review, the pathophysiology of diabetic cardiomyopathy is discussed, with an emphasis on the molecular and cellular irregularities that arise as the condition progresses, as well as existing and prospective future treatments. Method: The literature for this topic was researched utilizing Google Scholar as a search engine. Before compiling the review article, several research and review publications from various publishers, including Bentham Science, Nature, Frontiers, and Elsevier, were investigated. Result: The abnormal cardiac remodelling, marked by left ventricular concentric thickening and interstitial fibrosis contributing to diastolic impairment, is mediated by hyperglycemia, and insulin sensitivity. The pathophysiology of diabetic cardiomyopathy has been linked to altered biochemical parameters, decreased calcium regulation and energy production, enhanced oxidative damage and inflammation, and a build-up of advanced glycation end products. Conclusion: Antihyperglycemic medications are essential for managing diabetes because they successfully lower microvascular problems. GLP-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors have now been proven to benefit heart health by having a direct impact on the cardiomyocyte. To cure and avoid diabetic cardiomyopathy new medicines are being researched, including miRNA and stem cell therapies.Keywords
This publication has 136 references indexed in Scilit:
- Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic controlDiabetologia, 2022
- Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved TrialEuropean Journal of Heart Failure, 2019
- The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Left Ventricular Function: Current Evidence and Future DirectionsESC Heart Failure, 2019
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal RiskJAMA, 2019
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art reviewDiabetologia, 2018
- The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat heartsHeart and Vessels, 2016
- Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?Cellular and Molecular Life Sciences, 2016
- Molecular mechanisms of diabetic cardiomyopathyDiabetologia, 2014
- Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivoBasic Research in Cardiology, 2012
- Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patientsHeart and Vessels, 2011